These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 25450804)
21. Pharmacokinetic/pharmacodynamic modelling of the bactericidal activity of free lung concentrations of levofloxacin and gatifloxacin against Streptococcus pneumoniae. Tasso L; de Andrade C; Dalla Costa T Int J Antimicrob Agents; 2011 Oct; 38(4):307-13. PubMed ID: 21802907 [TBL] [Abstract][Full Text] [Related]
22. Antimicrobial susceptibility to levofloxacin and other antibacterial agents among common respiratory pathogens-a Brazilian perspective from the GLOBAL Surveillance Initiative 2001-2002. Mendes C; Kiffer CR; Blosser-Middleton RS; Jones ME; Karlowsky JA; Barth A; Rossi F; Andrade S; Sader HS; Thornsberry C; Sahm DF; Clin Microbiol Infect; 2004 Jun; 10(6):521-6. PubMed ID: 15191379 [TBL] [Abstract][Full Text] [Related]
23. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. Van Wart S; Phillips L; Ludwig EA; Russo R; Gajjar DA; Bello A; Ambrose PG; Costanzo C; Grasela TH; Echols R; Grasela DM Antimicrob Agents Chemother; 2004 Dec; 48(12):4766-77. PubMed ID: 15561855 [TBL] [Abstract][Full Text] [Related]
24. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics. Harrison CJ; Woods C; Stout G; Martin B; Selvarangan R J Antimicrob Chemother; 2009 Mar; 63(3):511-9. PubMed ID: 19174454 [TBL] [Abstract][Full Text] [Related]
25. [In vitro comparative activity of moxifloxacin and other antimicrobials against respiratory pathogens]. Prado V; Giangrieco M; Durán C; Ojeda A; van Flaskamp R Rev Med Chil; 2000 Dec; 128(12):1319-26. PubMed ID: 11227240 [TBL] [Abstract][Full Text] [Related]
26. Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in two university hospitals in Istanbul, Turkey. Gonullu N; Catal F; Kucukbasmaci O; Ozdemir S; Torun MM; Berkiten R Chemotherapy; 2009; 55(3):161-7. PubMed ID: 19390189 [TBL] [Abstract][Full Text] [Related]
27. Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia. Biedenbach DJ; Farrell DJ; Flamm RK; Liverman LC; McIntyre G; Jones RN Int J Antimicrob Agents; 2012 Apr; 39(4):321-5. PubMed ID: 22306239 [TBL] [Abstract][Full Text] [Related]
28. Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia. Öbrink-Hansen K; Hardlei TF; Brock B; Jensen-Fangel S; Kragh Thomsen M; Petersen E; Kreilgaard M Antimicrob Agents Chemother; 2015 Apr; 59(4):2398-404. PubMed ID: 25666151 [TBL] [Abstract][Full Text] [Related]
29. [Evaluation of efficacy of oral quinolone against Streptococcus pneumoniae AND Haemophilus influenzae with the use of Monte Carlo simulation]. Mikamo H; Tanaka K; Watanabe K Jpn J Antibiot; 2006 Dec; 59(6):468-73. PubMed ID: 17334064 [TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. Kontou P; Manika K; Chatzika K; Papaioannou M; Sionidou M; Pitsiou G; Kioumis I Int J Antimicrob Agents; 2013 Sep; 42(3):262-7. PubMed ID: 23830621 [TBL] [Abstract][Full Text] [Related]
31. Susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 17 oral antimicrobial agents based on pharmacodynamic parameters: 1998-2001 U S Surveillance Study. Jacobs MR; Bajaksouzian S; Windau A; Good CE; Lin G; Pankuch GA; Appelbaum PC Clin Lab Med; 2004 Jun; 24(2):503-30. PubMed ID: 15177851 [TBL] [Abstract][Full Text] [Related]
32. [Pharmacodynamic and pharmacokinetic evaluation of respiratory fluoroquinolones. Guideline to selection of the most appropriate fluoroquinolone]. Parra-Ruiz J; Hernández-Quero J Rev Esp Quimioter; 2012 Dec; 25(4):245-51. PubMed ID: 23303254 [TBL] [Abstract][Full Text] [Related]
33. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. Pfaller MA; Farrell DJ; Sader HS; Jones RN Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951 [TBL] [Abstract][Full Text] [Related]
34. Pharmacodynamic evaluation of commonly prescribed oral antibiotics against respiratory bacterial pathogens. Kiffer CR; Pignatari AC BMC Infect Dis; 2011 Oct; 11():286. PubMed ID: 22026724 [TBL] [Abstract][Full Text] [Related]
35. [Prediction on the efficacy of fluoroquinolones for anaerobic infections using Monte Carlo simulation]. Mikamo H; Tanaka K; Watanabe K Jpn J Antibiot; 2007 Dec; 60(6):335-43. PubMed ID: 18447205 [TBL] [Abstract][Full Text] [Related]
36. Bacterial resistance in the new millennium. Its impact on antibiotic selection for respiratory tract infections. Appelbaum PC Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):5-16. PubMed ID: 19667544 [TBL] [Abstract][Full Text] [Related]
37. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. Stass H; Dalhoff A Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709 [TBL] [Abstract][Full Text] [Related]
38. Activities of BMS 284756 (T-3811) against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from SENTRY antimicrobial surveillance program medical centers in Latin America (1999). Gales A; Sader H; Jones RN; Antimicrob Agents Chemother; 2001 May; 45(5):1463-6. PubMed ID: 11302811 [TBL] [Abstract][Full Text] [Related]